Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-06-11 8:39 pm Purchase |
2025-06-09 | 13D | Eterna Therapeutics Inc. ERNA |
Charles Cherington | 41,690,775 37.900% |
21,258,141 (+104.04%) |
Filing History |
| 2025-05-15 9:13 pm Purchase |
2025-03-31 | 13G | Eterna Therapeutics Inc. ERNA |
John D. Halpern | 5,971,830 9.600% |
835,249 (+16.26%) |
Filing History |
| 2025-05-15 4:42 pm Purchase |
2025-03-31 | 13G | Eterna Therapeutics Inc. ERNA |
Konar Shameek | 3,435,304 5.500% |
3,435,304 (New Position) |
Filing History |
| 2025-05-14 8:39 pm Purchase |
2025-03-31 | 13G | Eterna Therapeutics Inc. ERNA |
IAF, LLC | 3,255,421 5.200% |
576,207 (+21.51%) |
Filing History |
| 2025-05-14 2:14 pm Purchase |
2025-03-31 | 13G | Eterna Therapeutics Inc. ERNA |
Freebird Partners LP | 6,211,530 9.900% |
1,074,834 (+20.92%) |
Filing History |
| 2025-04-04 10:55 am Purchase |
2025-04-02 | 13D | Eterna Therapeutics Inc. ERNA |
Charles Cherington | 20,432,634 32.800% |
3,790,451 (+22.78%) |
Filing History |
| 2025-03-05 5:55 pm Purchase |
2024-10-29 | 13D | Eterna Therapeutics Inc. ERNA |
Charles Cherington | 16,642,183 32.380% |
15,429,657 (+1272.52%) |
Filing History |
| 2025-02-14 9:30 pm Purchase |
2024-12-31 | 13G | Eterna Therapeutics Inc. ERNA |
Nicholas Jason Singer | 2,565,001 4.920% |
1,964,521 (+327.16%) |
Filing History |
| 2025-02-14 8:36 pm Purchase |
2024-10-29 | 13G | Eterna Therapeutics Inc. ERNA |
John D. Halpern | 5,136,581 9.990% |
5,136,581 (New Position) |
Filing History |
| 2025-02-12 5:54 pm Purchase |
2024-10-29 | 13G | Eterna Therapeutics Inc. ERNA |
IAF, LLC | 2,679,214 5.220% |
2,102,250 (+364.36%) |
Filing History |
| 2025-01-28 5:31 pm Purchase |
2024-10-29 | 13G | Eterna Therapeutics Inc. ERNA |
Freebird Partners LP | 5,136,696 9.990% |
4,083,209 (+387.59%) |
Filing History |
| 2024-01-31 07:05 am Purchase |
2023-12-31 | 13G | Eterna Therapeutics Inc. ERNA |
John D. Halpern | 550,894 9.990% |
98,611 (+21.80%) |
Filing History |
| 2024-01-19 10:31 am Purchase |
2023-12-31 | 13G | Eterna Therapeutics Inc. ERNA |
Nicholas Jason Singer | 600,480 9.990% |
43,070 (+7.73%) |
Filing History |
| 2023-12-22 12:05 pm Unchanged |
2023-12-14 | 13D | Eterna Therapeutics Inc. ERNA |
Charles Cherington | 1,212,526 19.990% |
0 (Unchanged) |
Filing History |
| 2023-12-20 3:24 pm Purchase |
2023-12-14 | 13G | Eterna Therapeutics Inc. ERNA |
IAF, LLC | 576,964 9.990% |
576,964 (New Position) |
Filing History |
| 2023-09-08 06:07 am Unchanged |
2023-07-06 | 13G | Eterna Therapeutics Inc. ERNA |
Nicholas Jason Singer | 557,410 9.900% |
0 (Unchanged) |
Filing History |
| 2023-09-07 5:26 pm Purchase |
2023-07-13 | 13D | Eterna Therapeutics Inc. ERNA |
Charles Cherington | 1,212,526 19.990% |
645,000 (+113.65%) |
Filing History |
| 2023-08-28 4:57 pm Purchase |
2023-04-03 | 13G | Eterna Therapeutics Inc. ERNA |
Purchase Capital LLC | 280,422 5.000% |
280,422 (New Position) |
Filing History |
| 2023-07-26 5:05 pm Purchase |
2023-04-03 | 13D | Eterna Therapeutics Inc. ERNA |
Nicholas Jason Singer | 557,410 9.990% |
557,410 (New Position) |
Filing History |
| 2023-07-20 7:52 pm Purchase |
2023-07-14 | 13G | Eterna Therapeutics Inc. ERNA |
Freebird Partners LP | 1,053,487 19.990% |
355,976 (+51.04%) |
Filing History |